organization · Reporting owner
HSAC 2 Holdings, LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Orchestra BioMed Holdings, Inc.
Report date August 05, 2024 · Filed August 07, 2024
Section 16 reporting ended · disclosed 2024-08-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,705,705 |
Reported balance
After 2024-08-05 transaction · row 1
1 source rowRow 1 · 2024-08-05 · Other · Disposed 3,405,251 · Balance 1,705,705 F1: The Reporting Person distributed the shares pro-rata to certain of its members. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person distributed the shares pro-rata to certain of its members.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 05, 2024 Filed Aug 7, 2024 21:16 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | OtherCommon Stock | 3,405,251 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-014634 · form4.xml · nonDerivative · entry 1 HSAC 2 Holdings, LLC · CIK 0001814116 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,705,705 F1 · kind: The Reporting Person distributed the shares pro-rata to certain of its members. Read SEC document |
| August 06, 2020 Filed Aug 6, 2020 18:53 UTC | Orchestra BioMed Holdings, Inc. HSAQ · Entity 434 | PurchaseWarrants to purchase Ordinary Shares · Derivative | 1,500,000 | $1.00 Strike: $11.50 | $1,500,000.00 |
DisclosureSEC source: 0001213900-20-020613 · ownership.xml · derivative · entry 2 HSAC 2 Holdings, LLC · CIK 0001814116 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500,000 Underlying: Ordinary Shares · 1,500,000 shares Expires not disclosed F1 · derivative.exercise_date: The warrants become exercisable on the later of (i) the completion of the registrant's initial business combination and (ii) 12 months from the closing of the registrant's initial public offering. F2 · derivative.expiration_date: The warrants expire 5 years after the completion of the registrant's initial business combination or earlier upon redemption or liquidation, as described in the registrant's prospectus filed with the SEC. Read SEC document |
| August 06, 2020 Filed Aug 6, 2020 18:53 UTC | Orchestra BioMed Holdings, Inc. HSAQ · Entity 434 | PurchaseOrdinary Shares | 450,000 | $10.00 | $4,500,000.00 |
DisclosureSEC source: 0001213900-20-020613 · ownership.xml · nonDerivative · entry 1 HSAC 2 Holdings, LLC · CIK 0001814116 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,360,956 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.